Quanterix Co. (NASDAQ:QTRX) Shares Sold by Ashford Capital Management Inc.

Ashford Capital Management Inc. decreased its position in Quanterix Co. (NASDAQ:QTRX - Free Report) by 25.8% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 544,530 shares of the company's stock after selling 189,585 shares during the period. Ashford Capital Management Inc. owned about 1.41% of Quanterix worth $5,788,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Resona Asset Management Co. Ltd. purchased a new stake in shares of Quanterix in the 4th quarter worth about $55,000. Tower Research Capital LLC TRC raised its position in shares of Quanterix by 219.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,702 shares of the company's stock worth $61,000 after purchasing an additional 3,915 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Quanterix in the 4th quarter valued at approximately $66,000. Canada Pension Plan Investment Board lifted its stake in Quanterix by 64.5% in the 4th quarter. Canada Pension Plan Investment Board now owns 10,200 shares of the company's stock valued at $108,000 after buying an additional 4,000 shares in the last quarter. Finally, ProShare Advisors LLC acquired a new stake in Quanterix during the 4th quarter valued at $108,000. Hedge funds and other institutional investors own 86.48% of the company's stock.

Quanterix Trading Up 0.4%

QTRX traded up $0.02 during midday trading on Friday, hitting $4.85. The company's stock had a trading volume of 409,846 shares, compared to its average volume of 573,581. Quanterix Co. has a 52-week low of $4.05 and a 52-week high of $19.18. The firm has a 50-day moving average price of $5.64 and a two-hundred day moving average price of $8.48. The firm has a market cap of $188.32 million, a P/E ratio of -4.58 and a beta of 1.12.

Quanterix (NASDAQ:QTRX - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.69) by $0.16. The firm had revenue of $30.33 million during the quarter, compared to the consensus estimate of $28.27 million. Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. On average, equities analysts expect that Quanterix Co. will post -0.98 EPS for the current year.

Analyst Upgrades and Downgrades

QTRX has been the subject of a number of analyst reports. Canaccord Genuity Group cut their price target on Quanterix from $15.00 to $12.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Wall Street Zen downgraded shares of Quanterix from a "hold" rating to a "sell" rating in a report on Thursday. Leerink Partners reissued a "market perform" rating and issued a $8.00 price objective (down previously from $12.00) on shares of Quanterix in a research report on Wednesday, April 30th. Leerink Partnrs lowered shares of Quanterix from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 30th. Finally, Scotiabank reaffirmed an "outperform" rating on shares of Quanterix in a research note on Tuesday, March 25th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat.com, Quanterix currently has a consensus rating of "Hold" and an average price target of $15.60.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.